

## **Notice of Completion of Acquisition of Own Shares**

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, July 13, 2015 – Astellas Pharma Inc. (Tokyo : 4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that it completed acquisition of its own shares, which was resolved by its Board of Directors on May 26, 2015, pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

### Particulars

- |  |                                       |
|--|---------------------------------------|
| 1. Class of shares acquired:             | Common stock of the Company           |
| 2. Total number of shares acquired:      | 20,000,000 shares                     |
| 3. Aggregate amount of acquisition cost: | 35,619,462,550 yen                    |
| 4. Period of acquisition:                | From May 28, 2015 to July 10, 2015    |
| 5. Method of acquisition:                | Purchased on the Tokyo Stock Exchange |

### (Reference)

Details of the resolution at the meeting of the Board of Directors (announced on May 26, 2015)

- |  |   |
|--|---|
| - Class of shares to be acquired:        | Common stock of the Company   |
| - Total number of shares to be acquired: | Up to 20 million shares<br>(The percentage compared to the total number of shares outstanding: 0.91%) |
| - Aggregate amount of acquisition cost:  | Up to 40 billion yen  |
| - Period of acquisition:                 | From May 28, 2015 to July 24, 2015  |

#####

For inquiries or additional information
Astellas Pharma Inc. Corporate Communications TEL: +81-3-3244-3201, FAX:+81-3-5201-7473 <a href="http://www.astellas.com/en">http://www.astellas.com/en</a>